Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer has reported the discontinuation of a Phase III clinical trial of single-agent tremelimumab in patients with advanced melanoma, after the review of interim data showed that the trial would not demonstrate superiority to standard chemotherapy.
Subscribe to our email newsletter
Pfizer has communicated with worldwide regulatory authorities and investigators regarding the discontinuation of the trial. Investigators will work with their patients to determine if they are benefiting from treatment and therefore should continue treatment with tremelimumab.
Charles Baum, vice president and oncology therapeutic area head at Pfizer global R&D, said: “We will continue to focus on additional studies involving tremelimumab alone and in combination with other therapies which are currently ongoing in patients with several types of cancer. We will continue to assess the study data to understand the clinical benefit seen in some patients who received tremelimumab.”